• Explore /
  • Poster
  • / MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.

MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma—Trial in progress.

Abstract Video & Slides Poster

Authors

Daniel Catenacci

Daniel V.T. Catenacci

Gastrointestinal Oncology Program, University of Chicago, Chicago, IL

Daniel V.T. Catenacci , John H. Strickler , Yoshiaki Nakamura , Kohei Shitara , Yelena Y. Janjigian , Afsaneh Barzi , Tanios S. Bekaii-Saab , Heinz-Josef Lenz , Hyun Cheol Cheol Chung , Josep Tabernero , Takayuki Yoshino , Salvatore Siena , Joal Garrido Mayor , Maria Corinna Palanca-Wessels , Diqiong Xie , John Marshall

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Gastrointestinal Cancers Symposium

Session Type

Trials in Progress Poster Session

Session Title

Trials in Progress Poster Session A: Cancers of the Esophagus and Stomach and Other GI Cancers

Track

Esophageal and Gastric Cancer,Other GI Cancer

Sub Track

Therapeutics

Clinical Trial Registration Number

NCT04499924

DOI

10.1200/JCO.2022.40.4_suppl.TPS371

Abstract #

TPS371

Poster Bd #

M5

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: Haeseong Park

First Author: Fei Ma

First Author: Tanios S. Bekaii-Saab